ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Kyntra Bio and Biocad side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Kyntra BioBiocad
studies on the registry4194
open to participants now212
phase 3 studies under way115
reach primary completion within a year04
programswith a study of their own in two years210

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseKyntra BioBiocad
Phase 100%

Biocad: 2 of its 10 programs at phase 1

  1. BCD-256phase 1
  2. BCD-261phase 1
20%
Phase 2

Kyntra Bio: 1 of its 2 programs at phase 2

  1. Anti-CD46 Antibody-drug Conjugate FOR46phase 2
50%

Biocad: 2 of its 10 programs at phase 2

  1. anti-TL1A monoclonal antibody, low dosephase 2
  2. BCD-236phase 2
20%
Phase 300%

Biocad: 6 of its 10 programs at phase 3

  1. divozilimabphase 3
  2. BCD-248phase 3
  3. pegdarbepoetin betaphase 3
  4. BCD-281phase 3
  5. Adalimumabphase 3

and 1 more — sign in to see them all

60%
Approved, new studies

Kyntra Bio: 1 of its 2 programs at approved, new studies

  1. roxadustatapproved, new study
50%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Kyntra Bio0 readouts · 0 phase 3············
Biocad1 readouts · 0 phase 3··

Biocad, Jan ’27: 1 program whose next study reaches primary completion

  1. anti-TL1A monoclonal antibody, low dosephase 2 · Jan 0 · NCT07080034
·········
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Kyntra Bio

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Biocad

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionKyntra BioBiocad
Anemiaboth · compare here

Kyntra Bio in Anemia: 1 program

  1. roxadustatapproved, new study

Their studies: Kyntra Bio’s studies of Anemia in search

Biocad in Anemia: 1 program

  1. pegdarbepoetin betaphase 3

Their studies: Biocad’s studies of Anemia in search

Multiple Myelomaboth · compare here

Kyntra Bio in Multiple Myeloma: 1 program

  1. Anti-CD46 Antibody-drug Conjugate FOR46phase 2

Their studies: Kyntra Bio’s studies of Multiple Myeloma in search

Biocad in Multiple Myeloma: 1 program

  1. BCD-248phase 3

Their studies: Biocad’s studies of Multiple Myeloma in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Kyntra Bio 2 of 2 · Biocad 2 of 10 programs (4 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.